|
Free Writing Prospectus
|
|
|
(to the Preliminary Prospectus
|
|
|
Supplement dated February 28, 2023)
|
|
|
Filed Pursuant to Rule 433
|
|
|
Registration Statement No. 333-268633
|
|
|
5.685% Senior Notes Due 2026
|
|
|
Issuer:
|
The Cigna Group
|
|
Principal Amount:
|
$700,000,000
|
|
Trade Date:
|
February 28, 2023
|
|
Settlement*:
|
March 7, 2023 (T+5)
|
|
Maturity Date:
|
March 15, 2026
|
|
Issuer Ratings (Senior Debt)**:
|
Baa1 (Stable) by Moody’s Investors Service, Inc. / A- (Stable) by Standard & Poor’s Ratings Group Inc. / BBB+ (Stable) by Fitch Ratings Inc.
|
|
Coupon:
|
5.685%
|
|
Price to Public (percent of principal amount):
|
99.998% of principal amount
|
|
Yield to Maturity:
|
5.685%
|
|
Spread to Benchmark Treasury:
|
+117 basis points
|
|
Benchmark Treasury:
|
4.000% due February 15, 2026
|
|
Benchmark Treasury Price and Yield:
|
98-18
|
|
Interest Payment Dates:
|
March 15 and September 15, commencing September 15, 2023
|
|
Interest Payment Record Dates:
|
March 1 and September 1
|
|
Optional Redemption Provisions:
|
At any time prior to March 15, 2024, at the greater of: (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semi-annual basis (assuming a
360-day year consisting of twelve 30-day months) at the Treasury Rate plus 20 basis points less (b) interest accrued to the date of redemption, and (2) 100% of the principal amount of the Notes to be redeemed, plus, in either case, accrued
and unpaid interest thereon to the redemption date
|
|
Par Call Provision:
|
At any date after March 15, 2024 (two years prior to the Maturity Date), the Notes will be redeemable at par.
|
|
CUSIP / ISIN:
|
125523 CR9 / US125523CR91
|
|
5.400% Senior Notes Due 2033
|
|
|
Issuer:
|
The Cigna Group
|
|
Principal Amount:
|
$800,000,000
|
|
Trade Date:
|
February 28, 2023
|
|
Settlement*:
|
March 7, 2023 (T+5)
|
|
Maturity Date:
|
March 15, 2033
|
|
Issuer Ratings (Senior Debt)**:
|
Baa1 (Stable) by Moody’s Investors Service, Inc. / A- (Stable) by Standard & Poor’s Ratings Group Inc. / BBB+ (Stable) by Fitch Ratings Inc.
|
|
Coupon:
|
5.400%
|
|
Price to Public (percent of principal amount):
|
99.906% of principal amount
|
|
Yield to Maturity:
|
5.412%
|
|
Spread to Benchmark Treasury:
|
+150 basis points
|
|
Benchmark Treasury:
|
3.500% due February 15, 2033
|
|
Benchmark Treasury Price and Yield:
|
96-20; 3.912%
|
|
Interest Payment Dates:
|
March 15 and September 15, commencing September 15, 2023
|
|
Interest Payment Record Dates:
|
March 1 and September 1
|
|
Optional Redemption Provisions:
|
At any time prior to December 15, 2032, at the greater of: (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semi-annual basis (assuming a
360-day year consisting of twelve 30-day months) at the Treasury Rate plus 25 basis points less (b) interest accrued to the date of redemption, and (2) 100% of the principal amount of the Notes to be redeemed, plus, in either case, accrued
and unpaid interest thereon to the redemption date
|
|
Par Call Provision:
|
At any date after December 15, 2032 (three months prior to the Maturity Date), the Notes will be redeemable at par.
|
|
CUSIP / ISIN:
|
125523 CS7 / US125523CS74
|
|
Joint Book-Running Managers:
|
BofA Securities, Inc.
Morgan Stanley & Co. LLC
U.S. Bancorp Investments, Inc.
|
|
Passive Bookrunners:
|
Citigroup Global Markets Inc.
HSBC Securities (USA) Inc.
J.P. Morgan Securities LLC
Mizuho Securities USA LLC
Wells Fargo Securities, LLC
|
|
Co-Managers:
|
Credit Agricole Securities (USA) Inc.
Credit Suisse Securities (USA) LLC
Deutsche Bank Securities Inc.
Goldman Sachs & Co. LLC
MUFG Securities Americas Inc.
PNC Capital Markets LLC
BNY Mellon Capital Markets, LLC
Fifth Third Securities, Inc.
RBC Capital Markets, LLC
Regions Securities LLC
Scotia Capital (USA) Inc.
SMBC Nikko Securities America, Inc.
TD Securities (USA) LLC
Truist Securities, Inc.
Academy Securities, Inc.
CastleOak Securities, L.P.
|
|
Use of Proceeds:
|
Cigna intends to use the net proceeds from this offering for general corporate purposes, which may include repayment of indebtedness.
|